)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Kalaris Therapeutics (KLRS) investor relations material
Kalaris Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focused on developing TH103, a novel anti-VEGF drug for retinal diseases, with ongoing Phase 1a and 1b/2 clinical trials in neovascular AMD and plans to expand into DME and RVO.
Initiated enrollment for Phase 1b/2 multiple ascending dose trial of TH103 in nAMD; Phase 1a single ascending dose trial remains on track for initial data by year end 2025.
No products approved or revenue generated; operations funded by equity, convertible notes, and $102.1M in cash from a merger with AlloVir.
Merger with AlloVir in March 2025 resulted in a reverse recapitalization, with Legacy Kalaris shareholders owning 74.47% of the combined company.
Entered agreement with KBI Biopharma for clinical supply manufacturing; opened new headquarters and hired a new CFO.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $77.0M as of September 30, 2025, up from $1.6M at December 31, 2024, primarily due to the merger with AlloVir.
Net loss for Q3 2025 was $11.9M, compared to $38.1M in Q3 2024; net loss for the nine months ended September 30, 2025 was $33.4M, down from $47.1M in the prior year period.
Research and development expenses for the nine months ended September 30, 2025 were $23.6M, down from $41.2M year-over-year, primarily due to a $32.1M one-time royalty obligation expense in 2024.
General and administrative expenses increased to $11.8M for the nine months ended September 30, 2025, up from $3.4M year-over-year, mainly due to higher legal, accounting, insurance, and personnel costs post-merger.
No revenue recognized; all funding from financing activities.
Outlook and guidance
Cash runway expected to fund operations into 2027 based on current plans.
Initial clinical data from the Phase 1a trial of TH103 expected by year-end 2025; Phase 1b/2 data expected in the second half of 2026.
Anticipates continued operating losses and need for additional capital to advance development and commercialization.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kalaris Therapeutics earnings date
Q4 20256 Mar, 2026
Next Kalaris Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage